Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Does Amarin Have the Right Management Team?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Biopharmaceutical company Amarin (Nasdaq: AMRN  ) won approval from the Food and Drug Administration for its hypertriglyceridemia drug Vascepa in July. Speculation surrounding an Amarin buyout has ebbed and flowed in the past few months. Most recently, rumors emerged that AstraZeneca (NYSE: AZN  )  -- a struggling pharma giant that could turn the page with its new chief executive -- might be interested in making a bid. If opportunity knocks and Amarin does in fact receive an offer, can investors trust the company's management to negotiate a good deal?

To help you weigh both the opportunities and risks associated with this stock, we're launching a brand new premium report on Amarin. The following – which focuses on Amarin's leadership-is only a small sample of what you'll find in the complete report.

Amarin has had five different chief executives over the past decade, but it currently has the ideal management team to carry the company forward. CEO Joseph Zakrzewski is an industry veteran who served as the COO of Reliant Pharmaceuticals -- which coincidentally licensed the U.S. rights to Lovaza from Norwegian drugmaker ProNova BioPharma.

That's right: Amarin's CEO was an integral part of the company that commercialized Vascepa's chief competitor in the hypertriglyceridemia space. Zakrzewski was also at Reliant when the company was sold to GlaxoSmithKline  (NYSE: GSK  )  in 2007 for a hefty $1.65 billion. I bet he knows his way around a negotiating table, and these skills might come in handy if Amarin starts to aggressively look for a buyer.

Amarin also has a management team that can capably launch Vascepa if it decides to fly solo. The company's chief commercial officer, Paul Huff, and president of R&D, Steven Ketchum, also held senior management positions at Reliant during the commercialization of Lovaza.

We hope you enjoyed this sample of our new premium research report on Amarin. To gain access to the complete report and a full year of updates, click here to keep reading today.

Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 01, 2012, at 5:17 PM, NoPanicBill wrote:

    All the more reason to buy Jun call options at a strike pice of $15. It seems to me to be a no brainier because AMRN will be announcing their application for FDA approval of their Anchor study for >200 to <500 research in November or December. Approval seems positive by late spring. Add all the new Patents that have been granted these past few days with more to come enhances that it is becoming a possibility that NCE may be granted in either of these two months. These are the reasons I believe the June option is a no brainier.

  • Report this Comment On November 01, 2012, at 5:32 PM, skm1965 wrote:

    Paul Huff marketed Lovaza and Niaspan.

    Note: He is Chief commercial officer.

    His compensation in 2011 was 6.8 mil.$ compared to Joe's 5.6 mil.$

    Joe joined in Jan.2011,Paul in Feb.2011.

    Marketing under Huff-- should be great.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2074140, ~/Articles/ArticleHandler.aspx, 10/28/2016 11:58:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,224.57 54.89 0.30%
S&P 500 2,137.81 4.77 0.22%
NASD 5,223.43 7.46 0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 11:42 AM
AMRN $3.14 Down -0.27 -7.92%
Amarin CAPS Rating: ****
AZN $28.50 Down -0.04 -0.14%
AstraZeneca CAPS Rating: ****
GSK $40.16 Down -0.26 -0.64%
GlaxoSmithKline CAPS Rating: ***